HSPBAP1 Antibody

What is HSPBAP1 and what are its known biological functions?

HSPBAP1 (Heat Shock Protein B Associated Protein 1), also known as Protein associated with small stress protein 1 or PASS1, is a widely expressed 488 amino acid protein that plays a significant role in regulating cellular stress response . The protein has multiple isoforms with molecular weights of approximately 55, 50, 32, and 25 kDa . Its calculated molecular weight is 55 kDa, though it is often observed at 55-60 kDa in experimental systems .

HSPBAP1's primary function appears to be associated with the regulation of stress response pathways in living cells, as indicated by multiple studies . The protein has been implicated in modulating the activity of heat shock proteins, particularly through its interactions with heat shock complexes that may influence cellular protection mechanisms against various stressors .

Which HSPBAP1 antibodies are available for research applications and what are their characteristics?

Several validated HSPBAP1 antibodies are available for research applications, each with specific characteristics:

These antibodies have been validated through various applications including Western blot analysis, immunohistochemistry, and ELISA, demonstrating their specificity for detecting HSPBAP1 in experimental systems .

How is HSPBAP1 expression distributed in different tissue types?

HSPBAP1 demonstrates wide tissue distribution, though expression levels may vary across different cell and tissue types. Immunohistochemistry studies have successfully detected HSPBAP1 in several tissues, including:

• Mouse kidney tissue

• Human prostate cancer tissue

• Human colon carcinoma tissue

Additionally, positive Western blot detection has been reported in:

• HeLa cells (human cervical cancer cell line)

• PC-3 cells (human prostate cancer cell line)

• A549 cells (human lung carcinoma cell line)

The wide expression pattern suggests HSPBAP1 may serve fundamental cellular functions across multiple tissue types, though its expression might be altered in certain pathological conditions .

How does HSPBAP1 interact with heat shock proteins and what is the functional significance?

HSPBAP1 demonstrates important functional interactions with heat shock proteins, particularly Hsp70, which has significant implications for cellular stress response mechanisms. Research indicates that HSPBAP1 can modulate the activity of heat shock protein complexes .

A key finding from available research is that HSPBAP1 can inhibit the cytotoxic activity of the Tag7-Hsp70 complex. Experimental evidence shows that when HSPBAP1 is added to the Tag7-Hsp70 complex, there is a dose-dependent decrease in cytotoxicity . At equimolar concentrations, HSPBAP1 reduces the maximal cytotoxic activity by approximately 50%, while a 5-fold greater concentration completely eliminates the cytotoxic effect .

This inhibitory interaction suggests that HSPBAP1 may serve as a regulatory component in stress-induced cell death pathways, potentially protecting cells from excessive damage during stress conditions by modulating heat shock protein complex activities .

What is known about HSPBAP1's association with pathological conditions?

While research on HSPBAP1's role in disease states is still emerging, several significant associations have been identified:

A chromosomal aberration involving HSPBAP1 has been found in a family with renal carcinoma, suggesting a potential role in cancer development or progression . The specific molecular mechanisms linking this chromosomal abnormality to carcinogenesis remain to be fully elucidated.

Additionally, immunohistochemical studies have detected HSPBAP1 in various cancer tissues, including prostate cancer and colon carcinoma specimens . This expression pattern in malignant tissues warrants further investigation into whether HSPBAP1 functionally contributes to cancer cell biology or represents a response to the altered cellular environment in cancer.

The protein's involvement in stress response pathways, particularly through its interaction with heat shock proteins, may have broader implications for various pathological conditions characterized by dysregulated stress responses, though these connections require additional research to confirm .

What is the significance of the HSPBAP1 core domain in protein function?

The core domain of HSPBAP1, comprising amino acids 84-359, appears to retain many of the functional properties of the full-length protein . Experimental evidence indicates that this truncated version of HSPBAP1 exhibits similar biological activities to the complete protein in specific assay systems.

In particular, studies have shown that the core domain can effectively inhibit the cytotoxic activity of the Tag7-Hsp70 complex, mimicking the function of full-length HSPBAP1 . This finding suggests that the core region contains the essential structural elements required for HSPBAP1's regulatory interactions with heat shock protein complexes.

The preservation of functionality in the core domain has important implications for structure-function analyses and potential therapeutic applications targeting HSPBAP1. It indicates that the N-terminal (amino acids 1-83) and C-terminal (amino acids 360-488) regions may not be essential for certain key protein-protein interactions, though they might serve other regulatory or localization functions .

What are the optimal conditions for using HSPBAP1 antibodies in Western blot applications?

For optimal Western blot detection of HSPBAP1, researchers should consider the following protocol guidelines based on validated antibody performance:

Sample Preparation:

• Cell lines that have shown reliable HSPBAP1 expression include HeLa, PC-3, and A549 cells .

• Standard lysis buffers containing protease inhibitors are recommended to preserve protein integrity.

Antibody Dilutions:

• For polyclonal antibody 27631-1-AP: Use at 1:1000-1:8000 dilution

• For monoclonal antibody H00079663-M02 (Clone 1C4): Use at 1:500 dilution

• For polyclonal antibody ab228839: Use at 1:1000 dilution

Electrophoresis Conditions:

• 7.5-15% SDS-PAGE gels are suitable for resolving HSPBAP1, which has a predicted molecular weight of 55 kDa .

• Expected band size ranges from 55-60 kDa for the full-length protein, with additional isoforms potentially appearing at 50, 32, and 25 kDa .

Detection Method:

• Standard ECL (Enhanced Chemiluminescence) systems have been successfully used for visualization .

• Secondary antibodies should be matched to the host species of the primary antibody (anti-rabbit or anti-mouse as appropriate).

Controls:

• Positive controls using cell lines with confirmed HSPBAP1 expression are recommended.

• For monoclonal antibody validation, comparison between transfected and non-transfected cell lysates can help confirm specificity .

What are the recommended protocols for HSPBAP1 detection via immunohistochemistry?

For immunohistochemical detection of HSPBAP1 in tissue samples, researchers should follow these guidelines:

Tissue Preparation:

• Formalin-fixed, paraffin-embedded (FFPE) tissue sections have been successfully used for HSPBAP1 detection .

• Both normal tissues (e.g., mouse kidney) and pathological specimens (e.g., human prostate cancer, colon carcinoma) can be analyzed .

Antigen Retrieval:

• Recommended method: TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0

• Complete antigen retrieval is critical for optimal staining results.

Antibody Dilutions:

• For polyclonal antibody 27631-1-AP: Use at 1:50-1:500 dilution

• For polyclonal antibody ab228839: Use at 1:250 dilution for IHC-P

Staining Protocol:

• Standard indirect immunoperoxidase methods have been validated for HSPBAP1 detection.

• Appropriate blocking steps should be included to minimize background staining.

• HRP-conjugated secondary antibodies matched to the primary antibody host species should be used.

Visualization:

• DAB (3,3'-diaminobenzidine) is typically used as a chromogen for visualization.

• Nuclear counterstaining (e.g., with hematoxylin) can help with tissue architecture interpretation.

Controls:

• Positive control tissues with known HSPBAP1 expression should be included in each staining run.

• Negative controls (omitting primary antibody) are essential to confirm staining specificity.

How can researchers effectively detect intracellular versus membrane-bound HSPBAP1?

HSPBAP1 may be present in different cellular compartments, and specific techniques have been validated for differentiating between intracellular and membrane-bound populations:

Flow Cytometry:
For detecting membrane-bound extracellular HSPBAP1:

• Stain live, non-permeabilized cells with appropriate markers (e.g., R-Phycoerythrin-labeled CD8 antibodies for lymphocytes)

• Follow with HSPBAP1 primary antibody (e.g., sheep anti-HspBP1)

• Detect using fluorochrome-conjugated secondary antibody (e.g., FITC-conjugated donkey anti-sheep IgG)

• Fix cells with 1% paraformaldehyde prior to analysis

For detecting intracellular HSPBAP1:

• Stain cells for surface markers if needed

• Fix and permeabilize cells using commercial kits (e.g., FIX & PERM kit)

• Stain with HSPBAP1 primary antibody

• Detect using fluorochrome-conjugated secondary antibody

• Analyze samples using flow cytometer in the logarithmic channel of fluorescence

Confocal Microscopy:
For intracellular visualization:

• Fix and permeabilize cells using appropriate kits

• Stain with anti-HSPBAP1 antibodies

• Detect using fluorochrome-conjugated secondary antibodies (e.g., Alexa488-conjugated anti-sheep IgG)

• Wash with PBS and 50 mM NH₄Cl

• Mount specimens in antifade reagent (e.g., ProLong Gold)

• Analyze using confocal microscopy

These complementary approaches allow researchers to determine the subcellular localization of HSPBAP1 and potentially correlate this with functional studies.

How should researchers interpret multiple bands when detecting HSPBAP1 via Western blot?

When performing Western blot analysis of HSPBAP1, researchers may observe multiple bands, which requires careful interpretation:

Expected Band Pattern:

• The primary band for full-length HSPBAP1 should appear at approximately 55-60 kDa, consistent with its calculated molecular weight of 55 kDa .

• Additional bands may be detected at approximately 50, 32, and 25 kDa, representing known isoforms of HSPBAP1 .

Interpretation Guidelines:

• Isoform Identification: Multiple bands may represent legitimate HSPBAP1 isoforms. The presence of bands at 55, 50, 32, and 25 kDa is consistent with documented HSPBAP1 isoforms and should not necessarily be interpreted as non-specific binding .

• Cell Type Considerations: The expression pattern of HSPBAP1 isoforms may vary across different cell types. For example, certain isoforms might be preferentially expressed in specific tissues or under certain conditions, such as cellular stress .

• Validation Approaches: If uncertain about band identity, researchers should consider:

  • Comparing patterns across multiple HSPBAP1 antibodies targeting different epitopes

  • Using positive controls with known HSPBAP1 expression patterns

  • Testing samples from HSPBAP1 knockdown or knockout models to confirm band specificity

• Post-translational Modifications: Bands that appear slightly higher than the predicted molecular weight (e.g., the 55-60 kDa observed versus 55 kDa calculated) may represent post-translationally modified forms of HSPBAP1 .

Understanding this complexity in HSPBAP1 detection is essential for accurate data interpretation and experimental planning.

What controls are essential when studying HSPBAP1 interactions with other proteins?

When investigating HSPBAP1's interactions with partner proteins such as Tag7 and Hsp70, several critical controls should be implemented:

Essential Controls for Interaction Studies:

• Individual Protein Controls:

  • Test each protein individually (e.g., HSPBAP1, Tag7, Hsp70) in functional assays to establish baseline activities .

  • For example, research has shown that while the Tag7+Hsp70 pair demonstrates cytotoxic activity, individual proteins or other combinations (Hsp70+HspBP1, Tag7+HspBP1) show no cytotoxicity .

• Concentration Gradients:

  • Test protein interactions at varying molar ratios to establish dose-dependent effects .

  • Research demonstrates that equimolar concentrations of HspBP1 decrease Tag7-Hsp70 cytotoxicity by half, while a 5-fold excess completely eliminates activity .

• Domain-Specific Controls:

  • Use truncated protein variants (e.g., the core domain of HSPBAP1, amino acids 84-359) to identify specific interaction domains .

  • Compare activity of full-length versus truncated proteins to determine which domains are essential for functional interactions .

• Antibody Inhibition Controls:

  • Include anti-HSPBAP1 antibodies (typically at 10 μg/ml) in interaction experiments to block specific epitopes potentially involved in protein-protein interactions .

  • Compare with non-specific IgG (e.g., from sheep serum) at equivalent concentrations as a negative control .

• Immunoprecipitation Validations:

  • For co-immunoprecipitation experiments, include reciprocal pulldowns using antibodies against each interaction partner .

  • Include non-binding resin controls and IgG controls to account for non-specific binding .

Implementing these controls ensures that observed interactions represent specific biological phenomena rather than experimental artifacts.

How can researchers quantitatively assess HSPBAP1 concentration in experimental samples?

For accurate quantification of HSPBAP1 in experimental samples, researchers can employ several validated methodologies:

ELISA-Based Quantification:

• Enzyme-linked immunosorbent assays have been successfully used to determine HSPBAP1 concentrations in conditioned media and other biological samples .

• Both standard ELISA and sandwich ELISA formats have been validated for HSPBAP1 detection .

• For sandwich ELISA using monoclonal antibody H00079663-M02 (Clone 1C4), the detection limit for recombinant GST-tagged HSPBAP1 is approximately 0.3 ng/ml when used as a capture antibody .

Western Blot Densitometry:

• Semi-quantitative assessment can be performed using Western blot followed by densitometric analysis.

• This approach requires:

  • Including a standard curve of recombinant HSPBAP1 at known concentrations

  • Ensuring samples fall within the linear range of detection

  • Normalizing to appropriate loading controls

  • Using validated antibody dilutions (e.g., 1:1000-1:8000 for polyclonal antibody 27631-1-AP)

Flow Cytometry Quantification:

• For cellular HSPBAP1, flow cytometry can provide quantitative assessment of expression levels .

• This method allows for:

  • Analysis of distinct cell populations within heterogeneous samples

  • Correlation of HSPBAP1 expression with other cellular markers

  • Differentiation between intracellular and membrane-bound HSPBAP1 populations

  • Collection of statistically robust data from large cell numbers (typically ≥10⁴ cells)

These complementary approaches provide researchers with options for HSPBAP1 quantification across different experimental systems and research questions.

What are common challenges when working with HSPBAP1 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with HSPBAP1 antibodies across different applications. Here are common issues and recommended solutions:

Western Blot Challenges:

• Weak or Absent Signal:

  • Increase antibody concentration (start with manufacturer's recommended range, e.g., 1:1000-1:8000 for 27631-1-AP)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Ensure adequate protein loading (30 μg total protein is typically sufficient)

  • Verify transfer efficiency using reversible staining methods

• High Background:

  • Increase blocking time or concentration

  • Reduce primary antibody concentration

  • Add 0.1-0.5% Tween-20 to washing buffers

  • Ensure fresh ECL reagents for detection

Immunohistochemistry Challenges:

• Poor Staining Intensity:

  • Optimize antigen retrieval (try both TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Increase antibody concentration (e.g., adjust within 1:50-1:500 range for 27631-1-AP)

  • Extend primary antibody incubation time

  • Ensure tissue fixation was appropriate

• Non-specific Staining:

  • Optimize blocking (both protein blocking and endogenous peroxidase blocking)

  • Reduce primary antibody concentration

  • Include additional washing steps

  • Always include negative controls (omitting primary antibody)

Flow Cytometry Challenges:

• Low Signal-to-Noise Ratio:

  • Optimize fixation and permeabilization protocols (commercial kits like FIX & PERM have proven effective)

  • Titrate antibody concentrations

  • Use appropriate fluorochromes with minimal spectral overlap

  • Include proper compensation controls

• Cell Viability Issues:

  • Minimize processing time

  • Maintain cells at appropriate temperature

  • Include viability dyes to exclude dead cells from analysis

  • Use gentler fixation methods if needed

These optimization strategies should address most common challenges encountered when working with HSPBAP1 antibodies across different experimental applications.

How can researchers validate the specificity of HSPBAP1 antibodies for their experimental systems?

Validating antibody specificity is critical for ensuring reliable experimental results. For HSPBAP1 antibodies, several validation strategies have proven effective:

Genetic Validation:

• Knockdown/Knockout Comparison:

  • Compare antibody signal between wild-type samples and those with HSPBAP1 knockdown (siRNA/shRNA) or knockout (CRISPR/Cas9)

  • A specific antibody should show significantly reduced or absent signal in knockdown/knockout samples

• Overexpression Validation:

  • Compare signal between non-transfected cells and those overexpressing HSPBAP1

  • A specific antibody should show enhanced signal in overexpressing cells, as demonstrated for monoclonal antibody H00079663-M02 in transfected versus non-transfected 293T lysates

Biochemical Validation:

• Immunoprecipitation-Western Blot:

  • Immunoprecipitate HSPBAP1 using one antibody, then detect with a different antibody targeting a distinct epitope

  • This cross-validation approach confirms that both antibodies recognize the same protein

• Peptide Competition:

  • Pre-incubate antibody with excess immunizing peptide or recombinant HSPBAP1

  • A specific signal should be significantly reduced or eliminated in peptide-blocked samples

• Multiple Antibody Comparison:

  • Test multiple antibodies targeting different HSPBAP1 epitopes (e.g., polyclonal 27631-1-AP and monoclonal H00079663-M02)

  • Consistent detection patterns across different antibodies support specificity

Application-Specific Validation:

• Western Blot:

  • Confirm that observed bands match predicted molecular weights (55-60 kDa for full-length, with potential isoforms at 50, 32, and 25 kDa)

  • Verify consistency across different cell lines with known HSPBAP1 expression

• Immunohistochemistry:

  • Compare staining patterns with published literature

  • Confirm appropriate subcellular localization

  • Include positive control tissues with established HSPBAP1 expression

These complementary validation approaches provide robust confirmation of antibody specificity, ensuring reliable experimental outcomes when working with HSPBAP1.

What future research directions may advance our understanding of HSPBAP1?

Our current knowledge of HSPBAP1 suggests several promising avenues for future research that could significantly enhance our understanding of this protein's biological functions and potential clinical relevance.

The established connection between HSPBAP1 and cellular stress response pathways, particularly through its interactions with heat shock proteins like Hsp70 and the Tag7-Hsp70 complex, opens important questions about its broader role in cellular homeostasis and protection mechanisms . Future studies could explore how HSPBAP1 expression and activity are modulated under various stress conditions, potentially revealing new aspects of cellular stress adaptation.

The chromosomal aberration involving HSPBAP1 found in a family with renal carcinoma indicates a potential role in cancer biology that warrants deeper investigation . Researchers could examine HSPBAP1 expression patterns across diverse cancer types, explore potential mutations or alterations in its sequence or expression in malignant tissues, and investigate whether it could serve as a biomarker or therapeutic target.

The multiple isoforms of HSPBAP1 (55, 50, 32, and 25 kDa) suggest complex regulation at the transcriptional or post-transcriptional level . Future studies could characterize the specific functions of these different isoforms and determine whether they play distinct roles in cellular processes or disease states.

Additionally, the inhibitory effect of HSPBAP1 on Tag7-Hsp70 complex cytotoxicity suggests it may function as a regulator of cell death pathways . Further research could explore its potential role in modulating apoptosis, necroptosis, or other cell death mechanisms across various physiological and pathological contexts.

These research directions, supported by the continued development and validation of specific antibodies and other research tools targeting HSPBAP1, promise to yield valuable insights into this protein's biological significance and potential therapeutic relevance.

How should researchers integrate HSPBAP1 findings with broader stress response pathway studies?

As researchers continue to investigate HSPBAP1, integrating these findings within the broader context of cellular stress response pathways will be crucial for comprehensive understanding. The documented interaction of HSPBAP1 with heat shock proteins positions it as a potentially important component of cellular adaptation to stress conditions .

When designing experiments to study HSPBAP1 in stress response contexts, researchers should consider several methodological approaches:

• Stress Condition Panels: Examine HSPBAP1 expression and localization across multiple stress conditions (heat shock, oxidative stress, ER stress, hypoxia) to identify specific stress pathways where it plays significant roles.

• Temporal Analysis: Investigate the kinetics of HSPBAP1 expression and activity during stress induction, adaptation, and recovery phases to understand its temporal regulation.

• Pathway Integration: Study HSPBAP1 in relation to established stress response effectors, particularly heat shock proteins and their co-chaperones, to map its position within known stress response networks.

• Functional Consequences: Assess how HSPBAP1 modulation (overexpression, knockdown) affects cellular outcomes following stress exposure, including survival, damage repair, and adaptive responses.

• Cross-talk Analysis: Explore potential interactions between HSPBAP1 and other stress response pathways, such as the unfolded protein response, oxidative stress response, and DNA damage response.